Burt Zweigenhaft

Principal, Upstream Partners

Upstream Partners

Mr. Zweigenhaft is key industry thought leader and accomplished executive in the specialty-biotech pharmaceutical and oncology cancer care ecosystems. Mr. Zweigenhaft is the Managing Partner of Upstream-Partners, LLC. New York based Investment Company focused on incubating and launching new healthcare delivery services, specialty bio-pharmaceuticals, genomics, and precision medicine technologies into healthcare ecosystems. Mr. Zweigenhaft guidance has supported several key drug launch market strategies with industry leaders the likes of Genzyme, Pharmacyclics, Gilead, Janssen, Pfizer, Alexion, Bayer, GSK, Seattle Genetics, Sanofi, Monogram Science, Roche, Genentech, CureVax, Genomic Health, Massive Bio, Trio Health and emerging biotech incubators. Mr. Zweigenhaft serves as senior advisor to the shareholder group of Cancer Treatment Centers of America for pharmacy services and is the Past President of the National Association of Specialty Pharmacy (NASP), representing the industry on National Policy, Specialty Pharmacy Education and Government Relations based in Washington, DC. Previously Mr. Zweigenhaft held the office of CEO, Vice Chairman and Founder of Onco360 a national oncology pharmacy care management provider with corporate offices in NYC. The Onco360 model provided the full continuum of oncology pharmacy service solutions to over 3,000 community and hospital based Hematologists, Oncologists and Cancer Centers of Excellence in coordination with managed care providers insuring over 45 million people. Under Mr. Zweigenhaft vision and leadership Onco360 created, developed the industry standards for best practice oncology pharmacy model by incorporating the strengths of Board Certified Oncology Pharmacists and Oncology Patient Advocates to support the prospective and concurrent patient centered oncology medical home model. In 2014 PharMerica acquired controlling interest in Onco360 and relocated the company in 2015 to Louisville, KY. Mr. Zweigenhaft previously served as Senior Vice President of Managed Care Sales and Marketing, Government Programs, Trade Relations and Business Development Strategies for Priority Healthcare Corporation, a publicly traded company in the specialty pharmacy sector with $2.3 billion in specialty drug revenues before being acquired by Express Scripts in 2005. Prior to 2002, Mr. Zweigenhaft spent several years serving as a specialty pharmacy consultant to Medco, CuraScript, BioScrip and several Regional National Blue Cross Blue Shield and National Managed Care Payer programs. Mr. Zweigenhaft holds a Bachelor of Science in Management and Economics from the University of Buffalo School of Management, where he also serves on the Dean’s Advisory Committee and remains active with the University of Buffalo schools of Pharmacy and Medicine including the Center of Excellence for Bioinformatics and Health Sciences. Mr. Zweigenhaft is a member of AMCP (American Managed Care Pharmacy), HOPA (Hematology Oncology Pharmacists Association) and ASCO (American Society of Consulting Oncologists). Mr. Zweigenhaft also serves on the Editorial Boards of several industry publications and is Editor and Chief of the Journal for Value Based Cancer Care. Mr. Zweigenhaft is also Co-Chairman and Co-Founder of the AVBCC (Association for Value Based Cancer Care) and Founder and Past President of NASP (National Association of Specialty Pharmacy) in Washington, DC. Philanthropically Mr. Zweigenhaft serves on the National Board of Swim Across America for Cancer; a NFP organization that has raised $90 million to date to support cancer research laboratories. In 2015 Mr. Zweigenhaft was honored to be the recipient of the CancerCare “Help and Hope Award”.


200 Park Avenue, Suite 300 
Florham Park, NJ 07932





Asembia's Specialty Pharmacy Summit is a PRIVATE EVENT. Asembia reserves the right to deny registration and refuse access at our absolute and sole discretion for any reason whatsoever.

Terms & Conditions © 2019 Asembia Specialty Pharmacy Summit, LLC. All rights reserved.


  • Asembia LinkedIn
  • Asembia Twitter
  • Asembia Instagram
  • Asembia Facebook
  • Asembia Videos
  • Asembia Photos